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Statement of translational relevance: 
 
The clinical benefit of azacitidine (AZA) monotherapy in acute myeloid leukemia 
(AML) is blunted by low response rates and the inevitability of disease progression. 
Combination therapy with histone deacetylase (HDAC) inhibitors has been proposed 
to improve outcome but has not been prospectively studied in AML. The 
demonstration in this randomized study that co-administration of AZA with the HDAC 
inhibitor vorinostat does not improve outcome in newly diagnosed or relapsed AML 
confirms the importance of identifying new therapeutic partners for AZA. In this 
context the observation that mutations in the cell cycle checkpoint activator CDKN2A 
correlate with adverse clinical outcome represents the first clinical validation of in 
vitro data implicating induction of cell cycle arrest as a mechanism of AZA’s clinical 
activity informing the design of novel drug combinations. Furthermore, persistence of 
stem/progenitor populations throughout therapy identifies their role as a biomarker of 
response to AZA based regimens.  
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Abstract  
Purpose: Azacitidine (AZA) is a novel therapeutic option in older patients with acute 
myeloid leukemia (AML) but its rational utilization is compromised by the fact that 
neither the determinants of clinical response nor its mechanism of action are defined. 
Co-administration of histone deacetylase inhibitors, such as vorinostat (VOR), is 
reported to improve the clinical activity of AZA but this has not been prospectively 
studied in AML. Experimental Design: We compared outcomes in 259 adults with 
AML (n=217) and MDS (n=42) randomized to receive either AZA monotherapy (75 
mg/m2 × seven days every 28 days) or AZA combined with VOR 300 mg bd on days 
3-9 po. Next generation sequencing was performed in 250 patients on 41 genes 
commonly mutated in AML. Serial immunophenotyping of progenitor cells was 
performed in 47 patients. Results: Co-administration of VOR did not increase the 
overall response rate (P=0.84) or overall survival (OS) (P=0.32). Specifically, no 
benefit was identified in either de novo or relapsed AML. Mutations in the genes 
CDKN2A (P=0.0001), IDH1 (P=0.004) and TP53 (P=0.003) was associated with 
reduced OS. Lymphoid multi-potential progenitor populations were greatly expanded 
at diagnosis and although reduced in size in responding patients remained 
detectable throughout treatment. Conclusion: This study demonstrates no benefit of 
concurrent administration of VOR with AZA but identifies a mutational signature 
predictive of outcome after AZA based therapy. The correlation between 
heterozygous loss of function CDKN2A mutations and decreased OS implicates 
induction of cell cycle arrest as a mechanism by which AZA exerts its clinical activity. 
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Introduction 
The DNA methyltransferase (DNMT) inhibitors azacitidine (AZA) and decitabine 
(DEC) represent important advances in the management of patients with acute 
myeloid leukemia (AML) and high-risk myelodysplasia (MDS) ineligible for intensive 
chemotherapy (1). Recent randomized trials have demonstrated that AZA improves 
outcome in older adults with AML and high risk MDS (2, 3). More recently AZA has 
been to shown to possess significant clinical activity in relapsed and refractory AML 
(4-6). However, the clinical utility of AZA in both newly diagnosed and advanced 
disease is limited by relatively low rates of complete remission (CR) and the fact all 
patients relapse despite continuing therapy. There is consequently an urgent need to 
identify novel therapies with the potential to improve the outcome after AZA 
monotherapy. Co-administration of AZA with histone deacetylase (HDAC) inhibitors 
augments killing of leukemic cell lines in vitro (7) and single-arm trials have 
described increased clinical activity of AZA in combination with a number of HDAC 
inhibitors including sodium valproate and vorinostat (VOR) (4, 8, 9). Although recent 
randomized trials have reported no benefit of co-administration combined AZA and 
HDAC inhibitor therapy in high-risk MDS there have been no randomized trials in 
AML (10-12). 
The development of pharmacological strategies to improve the outcome of AZA 
based therapy in AML has been hampered by our limited understanding of its 
mechanism of action. Whilst in vitro and animal studies demonstrate that induction of 
cell cycle arrest and up-regulation of cell cycle genes correlates with AZA’s anti-
leukemic activity the mechanism by which it exerts a clinical anti-tumor effect 
remains a matter of conjecture (7). Furthermore, although disease progression 
appears inevitable in patients treated with AZA little is understood of the mechanism 
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of disease resistance (13). Recent immunophenotypic characterization of the 
stem/progenitor cell compartments containing leukemic stem cells (LSCs) in AML 
have demonstrated their persistence in a proportion of patients consistent with the 
hypothesis that this cellular population represents a reservoir of resistant disease 
although this proposition has not been prospectively examined in AZA treated 
patients (4, 14).  
We therefore examined whether co-administration of the HDAC inhibitor VOR 
increases response rates and OS in patients with AML and high risk MDS and 
correlated these clinical endpoints with both diagnostic genotypes and serial 
stem/progenitor quantitation. 
Subjects and Methods 
Trial design: RAvVA was a multi-center, open label, prospective randomized phase 
II trial designed to assess the activity and safety of AZA monotherapy compared to 
combined AZA and VOR therapy in AML and high-risk MDS patients 
(ISRCTN68224706, EudraCT 2011-005207-32) delivered by the Bloodwise Trials 
Acceleration Program (TAP). 
Patients: Patients with newly diagnosed, relapsed or refractory AML as defined by 
the World Health Organization (WHO) Classification or high-risk MDS (IPSS INT-2 or 
high-risk) according to the International Prognostic Scoring System (IPSS) deemed 
ineligible for IC on the grounds of age or co-morbidities were eligible for inclusion in 
this trial (Table 1) (15). A high presentation white count was not an exclusion to trial 
entry and patients were permitted to receive hydroxycarbamide after AZA 
administration for the first cycle of therapy. All patients required adequate renal and 
hepatic function and an Eastern Cooperative Oncology Group (ECOG) performance 
status ≤2 as a condition of trial entry. Patients with acute promyelocytic leukemia, a 
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prior allogeneic stem cell transplant or prior treatment with AZA or other DNMT 
inhibitors were ineligible.  
Treatment regimens: Patients were randomized on a 1:1 basis using a minimization 
algorithm with three variables: disease category (AML vs MDS), stage of disease 
(newly diagnosed vs relapsed / refractory) and age (<70 vs 70+). Patients in the 
control arm received AZA (75mg/m2) by subcutaneous (SC) injection on a five-two-
two schedule, commencing on day one of 28-day cycles for up to six cycles. In the 
combination arm patients received the same schedule of AZA in conjunction with 
additional VOR (300mg bd) orally (po) for seven consecutive days commencing on 
day three of each cycle. All study participants achieving a CR, CR with incomplete 
blood count recovery (CRi), marrow CR (mCR) or partial response (PR) within the 
first six cycles of treatment, were permitted to continue study treatment until loss of 
response. Non-responding patients discontinued trial therapy. Bone marrow samples 
for morphology and immunophenotypic assessment were collected after cycles three 
and six and three months thereafter. Compliance to treatment was defined as the 
number of patients who received treatment as planned according to the trial protocol.  
Efficacy endpoints: Two primary endpoints were defined: overall response rate 
(ORR) and overall survival (OS). ORR was defined as acquisition of CR, CRi, mCR 
or PR within six cycles of treatment utilizing modified Cheson or IWG criteria (16, 
17). For each patient the response after the third and sixth cycle of trial treatment 
was reviewed and the better of the two was considered the ‘best response’ and used 
here. OS was defined as the time from date of randomization to the date of death 
from any cause. Secondary outcome measures included CR/ CRi/ mCR rate within 
six cycles of trial therapy, duration of response defined as time from response to 
relapse, dose intensity defined as the total dose prescribed to each patient as a 
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proportion of the protocol dose and NCI CTCAE v4 defined grade ≥ three adverse 
event or SAE. Induction death was defined as death prior to the first response 
assessment. 
Next Generation Sequencing (NGS) and Bioinformatic analysis: Bone marrow 
aspirates were collected at diagnosis on consenting patients. Mutational analysis 
using NGS was performed on 250 diagnostic bone marrow samples. Genomic DNA 
was subjected to multiple x PCR on the Fluidigm Access Array. The panel consists 
of 904 amplicons across 41 genes frequently mutated in AML and myeloid 
malignancies, covering areas with high frequency of AML gene mutations (hotspots), 
or whole exons if no hotspots were previously reported in COSMIC (Supplemental 
Tables 1 and 2). Sequencing was performed on an Illumina MiSeq with 300 bp 
paired-end reads, yielding an average read depth of 912 reads per amplicon. 
Fluorescent capillary electrophoresis was performed in addition to NGS for the 
detection of FLT3 internal tandem duplications (ITDs), since the rate of detection of 
ITDs is ~60% using NGS alone (18). Details of Next Generation Sequencing 
methodology is provided within Supplementary Information (Supplementary Tables 
1, 2 and 3).  
Bioinformatic analysis 
Sequencing quality was assessed using FASTQC (Samtools) and aligned using a 
Burroughs-Wheeler Aligner algorithm in Stampy. A Phred score of 30 was set as a 
minimum quality threshold for variant calling. We used 2 variant callers: VARSCAN 
and Pindel, using the following parameters: minimum coverage 100 reads; minimum 
variant frequency 0.05; minimum read depth of variant 5; P value 0.05. As germline 
DNA was not available, we implemented criteria to optimize calling of disease-
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associated mutations and to exclude likely germline single-nucleotide polymorphisms 
or technical artefacts.  
Inclusion criteria for variant calling and filtering were as follows: (i) mutations in 
protein coding regions or conserved splice sites; and (ii) previous documentation as 
a somatic mutation in hematopoietic samples in COSMIC with a minimum variant 
allele frequency (VAF) of 0.05; or (iii) novel truncating variants (nonsense, 
deleterious missense/indels, variants affecting splicing) with a minimum VAF of 0.05; 
or (iv) novel single nucleotide variants with a minimum variant frequency of 0.1, if 
they cluster within 3 codons of a previously documented somatic variant reported in 
COSMIC or in the large AML dataset of Papaemmanuil NEJM 2016 (REF) ; v) SNVs 
with a VAF > 0.1 which did not meet the exclusion criteria below.  
Exclusion criteria for variants were the following: (i) variants predicted to result in a 
silent amino acid change; (ii) known polymorphisms present in human variation 
databases at a population frequency of > 0.0014 (0.14% reflecting the population 
incidence of myeloid disease); (iii) 1-bp indels present adjacent to regions of 4 
homopolymer bases at < 0.2 variant frequency; (iv) variants that occur in > 3 
samples of our cohort at a VAF of 0.05 to 0.1 that are not previously documented in 
COSMIC, which likely constitute PCR or sequencing artefacts in genomic regions 
prone to error. All putative variants were further validated by visualization using the 
Integrated Genome Viewer. 
Stem/progenitor immunophenotypic quantitation: Bone marrow (BM) aspirate 
samples were collected for sequential quantification of leukemic stem/progenitor 
populations pre-treatment, during treatment and at relapse. Mononuclear cells were 
isolated by Ficoll density gradient and viably frozen using 10% DMSO and stored in 
liquid nitrogen. Frozen mononuclear cells (MNCs) from BM samples were thawed on 
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the day of analysis, washed with Iscove’s Modified Dulbecco’s Medium (IMDM, 
Thermo Fisher Scientific, UK) supplemented with 10% fetal bovine serum (Sigma, 
UK) and 1mg/ml bovine pancreatic DNAse I (Sigma, UK). Cells were stained for 
FACS analysis as detailed below. FACS analysis was carried out on either BD LSR 
Fortessa or a BD FACSAria Fusion (Becton Dickinson, Oxford UK). 
Antibodies used in the lineage (Lin) depletion cocktail were: anti-CD2, anti-CD3, anti-
CD4, anti-CD8a, anti-CD10, anti-CD19, anti-CD20 and anti-CD235a. Antibodies 
used to analyze different subpopulations were: anti-CD34, anti-CD38, anti-CD90, 
anti-CD45RA, anti-CD123, anti-CD117, and 7AAD were used as a live/dead stain. 
Details of each antibody/streptavidin are listed in Supplemental Table 4. We did not 
deplete CD11b, CD14, CD7, CD56 expressing cells as these markers may be 
expressed by CD34+ and CD34-CD117+ LSC populations. We assessed LSC 
populations pre-treatment, during treatment and in a subset of patients, at relapse.  
Patients were selected for longitudinal LSC assessment based on availability of 
appropriate viably-banked samples and documented clinical outcome. The size of 
the stem/progenitor subpopulations of each sample were determined as a 
percentage of live Lin- MNCs, and expressed as a fold change of the upper limit 
values of normal control bone marrow (Supplemental Table 5). An example of the 
gating strategy is demonstrated in Supplemental Figure 1. 
Statistical analysis: The sample size was calculated on conventional phase III 
criteria but with a relaxed alpha and was originally powered to recruit 160 patients 
(ORR: P0= 15%, detectable difference=15%, 2-sided α and β =0.15, 0.2 respectively, 
OS control rate at one year=15%, detectable difference of 15%, 2-sided α and β=0.1, 
0.2 respectively). At two years based on the advice of the DMC the sample size was 
updated to 260 (ORR: P0=0.2, detectable difference=0.15, 2-sided α=0.1, β=0.15, 
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OS: P0=0.15, detectable difference=0.15, 2-sided α=0.1, β<10%). Given the 
increased sample size the final trial had sufficient power to investigate a trend of 
activity for both ORR and OS in a predetermined subgroup analysis of the newly 
diagnosed and advanced disease groups (detectable difference in ORR and 
OS=20% and 20% respectively, 2-sided α=0.2, β=0.2).   
Standard statistical methods were used for all analysis in the trial: Fisher exact or 
chi-squared tests for categorical endpoints (e.g. response), Kaplan Meier curves and 
log rank tests for time-to-event endpoints (e.g. survival), cumulative incidence curves 
and Cox models for time to event endpoints with competing risks (e.g. time to first 
response). In order to investigate clinical factors predicting outcome after AZA based 
therapy we performed logistic and Cox multivariable analysis on all trial patients for 
ORR and OS including treatment arm as a co-variable. Sub group analysis is 
presented using forest plots with test for interaction displayed. P values of 0.1 were 
considered significant for both primary outcomes and a P value of 0.05 was 
considered significant throughout the rest of the analysis. No multiple testing 
adjustments has been carried out as the analysis conducted was exploratory and 
hypothesis generating. Results 
Baseline characteristics of patients: Between November 2012 and September 
2015 260 patients were recruited from 19 UK centers as outlined in the consort 
diagram (Figure 1). One patient was randomized for a second time in error and 
removed from analysis. Baseline patient characteristics are listed in Table 1. Two 
hundred and seventeen patients had a diagnosis of AML at time of randomization 
and 42 patients with MDS. Of the 217 patients with AML 111 were newly diagnosed, 
73 had relapsed disease and 33 were refractory to at least one prior line of therapy. 
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Treatment administration and toxicities: Patients received a median of six cycles 
(IQR: 2, 8) of treatment in both arms of the trial. Average compliance to AZA across 
all cycles of treatment was 73% in the AZA arm and 71% in the combination arm. 
There was no difference in dose intensity across treatment arms with a median 
intensity of 100% of the dose delivered in the first six cycles of treatment. 106 
patients in the AZA arm experienced one or more toxicity compared to 110 patients 
in the combination arm and there was no difference between treatment arms 
(P=0.87). Adverse events (Grade 3 and 4) experienced by 5% or more of patients 
are listed in Supplemental Table 6. 
Response and survival: There was no difference in either ORR (41% versus 42%) 
(OR=1.05 (95% CI: 0.64, 1.72), P=0.84) or CR/CRi/mCR rate (22% and 26%) 
(OR=0.82 (95% CI: 0.46, 1.45), P=0.49) between the control and combination 
therapy arms. Time to first response and duration of response at one year was 
similar in the AZA and combination arm (6.2 vs 5.7 months and 67% vs 58% 
respectively) (Supplemental Figure 2). In pre-determined subgroup analysis patients 
with relapsed/refractory disease demonstrated an increased CR in the AZA/VOR 
arm (P=0.02), although this did not translate to an improvement in OS.  
No difference was observed in OS between patients treated with AZA monotherapy 
(median OS: 9.6 months (95% CI: 7.9, 12.7)) and patients in the AZA/VOR arm 
(median OS: 11.0 months (95% CI: 8.5, 12.0)) (HR=1.15 (95% CI: 0.87, 1.51), 
P=0.32). Specifically, there was no difference in OS between treatment arms in 
patients with newly diagnosed or relapsed/refractory AML (Figure 2)(Supplemental 
Figure 3).  
Clinical and molecular factors predicting outcome after AZA based therapy: 
We next wished to identify clinical factors predictive of response to AZA based 
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therapy in the trial cohort. Multivariable logistic regression demonstrated higher ORR 
rates in newly diagnosed disease vs refractory/relapsed disease (P=0.038). Neither 
diagnosis (AML vs MDS, P=0.22) nor presentation karyotype (favorable vs 
intermediate vs poor, P=0.76) predicted ORR in the same model. Cox regression 
analysis demonstrated increased OS in patients with MDS as opposed to AML 
(P=0.012), a low ECOG score (P=0.09) and a presentation WBC <10×109/l 
(P=0.019). Presentation karyotype did not correlate with OS. 
The impact of diagnostic mutational status on clinical response and OS was then 
studied using the results of NGS performed on 250 patients at trial entry (Figure 3A). 
The mean mutation number per patient was 3.4 (Figure 3B). Mutations in RUNX1 
were most frequent (73 patients, 29%). Mutations in DNMT3A (59 patients 23%), 
IDH2 (57 patients, 23%) and TET2 (56 patients, 22%) were also common (Figure 
3A). The observed mutational frequency was broadly consistent with that previously 
reported in older, but not younger, AML and MDS patients(19-21) (Figure 3C). In 
univariate analysis there was a lower complete response (CR, CRi, mCR) rate in 
patients with an IDH2 mutation (P=0.029) and STAG2 mutation (P=0.002) but an 
increased CR rate in patients with an NPM1 mutation (P=0.038) (Table 2). When 
considered in a multivariable analysis adjusted for all clinical variables, the presence 
of STAG2 and IDH2 mutations was not shown to have a significant association with 
acquisition of CR (Table 2). However, NPM1 mutation remained of prognostic 
significance (P=0.012). 
Mutations in CDKN2A (P=0.0001), IDH1 (P=0.004), TP53 (P=0.003), NPM1 
(P=0.037) and FLT3-ITD (P=0.04) were associated with reduced OS in univariate 
analysis. In multivariate analysis adjusted for all clinical variables, mutations in 
CDKN2A, IDH1 and TP53 were associated with decreased OS (Table 2). No 
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mutations were associated with improved OS. Mutations in ASXL1 (P=0.035) and 
ETV6 (P=0.033) were associated with a reduced duration of response. No mutations 
were associated with improved duration of response.  
Amongst other frequently co-occurring mutations, we observed significant co-
occurrence of NPM1 mutations with DNMT3A, FLT3-ITD, FLT3-other and IDH1 as 
well as DNMT3A with FLT3-other, IDH1 and IDH2 (P<0.05 for all comparisons). 
Patients with mutations in both DNMT3A and IDH1 had reduced OS (median OS 9.8 
months, 95% CI: 1.5-11.6 months) compared to patients without both mutations 
(median OS 10.7, 95%CI: 8.9-12). Patients with both NPM1 and IDH1 mutations had 
reduced OS (median OS 3.8 months, 95%CI: 1.6-NE) compared to patients without 
both mutations (median OS 10.7, 95%CI: 9.0-11.8). No significantly co-occurring 
mutations were found to be predictors of acquisition of CR (Figure 3D).  
Impact of AZA based therapy on the LSC population: An expanded CD34+ 
progenitor population was observed in 42/45 studied patients at diagnosis, while a 
CD34- expanded precursor population was observed in 3/45 (Figure 4A). The 
majority of expanded populations were lymphoid-primed multi-potential progenitors 
(LMPP: Lin-CD34+CD38-CD90-CD45RA+), which have been previously 
characterized as an LSC population with functional leukemia-propagating activity in 
serial xeno-transplant assays(14), and as a novel biomarker of AML disease 
response and relapse(4). Quantitatively, the immunophenotypic LMPP population is 
usually very small in normal bone marrow (<2 in 105 cells – Vyas et al data under 
review). Therefore, expansion of the LMPP population can be a sensitive measure of 
residual disease at CR in AML patients. For these reasons, we focused on 
quantitation LMPP by immunophenotyping to measure the impact of therapy on 
putative LSC populations at best response and relapse. 
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In seven patients with resistant disease, there was no reduction in LMPP numbers 
measured as a fold change (Figure 4B). Of interest, there was no significant 
reduction of LMPP numbers in eight patients achieving a PR, where the average 
bone marrow blast percentage was reduced by 50%. In contrast, in 22 CR/Cri/mCR 
patients there was a significant reduction in LMPP numbers with AZA-based therapy. 
However, even here LMPP numbers failed to normalize in 16/22 (Figure 4B). In 
seven patients with expanded LMPP numbers, who achieved a CR, sequential 
monitoring demonstrated expansion progenitor populations prior to disease relapse 
(Figure 4C).  
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Discussion 
Co-administration of the HDAC inhibitor VOR did not improve response or survival in 
patients with AML or MDS treated with AZA. This observation is consistent with 
previous randomized studies in high risk MDS but is the first demonstration that 
HDAC inhibitors have no impact on clinical outcomes in patients with newly 
diagnosed or relapsed AML treated with AZA (10-12). Why might our study have 
failed to replicate earlier single arm studies of strikingly increased clinical activity of 
combined AZA and HDAC inhibitor treatment (8, 9, 22)? Clinical and molecular 
characterization demonstrates comparability between study arms and confirms that 
the trial population was broadly representative of older patients with high-risk AML 
and MDS. Alternatively, the clinical activity of the experimental study arm might have 
been blunted because VOR associated drug toxicity resulted in under-dosing of AZA. 
Detailed pharmacovigilance excluded this possibility and indeed AZA dose intensity 
was similar in both treatment arms. Consideration should however be given to the 
possibility that co-administration of HDAC inhibitors might inhibit cellular uptake of 
aza-nucleosides and exploration of alternative dosing schedules may be worth 
exploring.  
The search for novel drug partners with the potential to improve the clinical activity of 
AZA has been hampered by the fact that its mechanism of clinical activity remains 
unknown. Cell line and animal data have identified up-regulation of epigenetically 
silenced genes and consequent restoration of cell cycle checkpoints as an important 
potential mechanism of action and indeed previous in vitro studies have correlated 
the ant-tumor activity of both AZA and DEC with their ability to effect changes in cell 
cycle gene expression and induce G2 phase arrest (7, 23, 24). Consequently, the 
observation that heterozygous predicted loss of function mutations in CDKN2A, a 
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cell cycle checkpoint activator, are correlated with decreased survival in AZA treated 
patients is supportive of the hypothesis that induction of cell cycle arrest is a 
potentially important mechanism of action of this agent. In our study the CDKN2A 
mutations were nonsense in two patients and in the other seven were either non-
synonymous SNVs that had previously been reported (six patients) or within two 
codons of a previously reported mutation (one patient). CDKN2A encodes P14, P16 
and ARF. P14 and P16 inhibit the cyclin dependent kinase CDK4 which regulates 
the G1 cell cycle checkpoint. ARF sequesters the E3 ubiquitin-protein ligase MDM2, 
a protein responsible for the degradation of p53. Thus, if loss of CDKN2A abrogates 
the clinical activity of AZA it raises the possibility that AZA induces G1 cell cycle 
arrest and requires at least some p53 function for its anti-leukemic activity. We 
acknowledge that the findings of this study are based on a small sample size and 
that it is important to replicate this clinical association of CDKN2A mutations with 
poor clinical response to AZA in larger studies. If confirmed, our data highlight further 
study of P14, P16 and ARF function as a potentially fruitful line of investigation in 
understanding and potentially improving the outcomes of AZA based therapy. 
The identification of both clinical and molecular predictors of outcome with AZA 
therapy is important if this agent is to be optimally deployed. Improved survival noted 
was observed in patients with newly diagnosed disease, a low presentation white 
count and ECOG score. Importantly, and in contrast to patients treated with 
myelosupressive chemotherapy, we observed no impact on survival of an adverse 
risk karyotype after AZA based therapy (25). Our data also demonstrate that NGS 
improves risk stratification since mutations in CDKN2A, IDH1 and TP53 were 
independently associated with decreased survival in AZA-treated patients. We did 
not identify any impact of mutations in TET2 or DNMT3A on outcome, in contrast to 
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previous smaller retrospective studies (26-29). Although TP53 mutations have 
previously been shown to be associated with decreased survival in patients treated 
with intensive chemotherapy (30) it has recently been reported that the presence of a 
TP53 mutation was associated with a higher response rate in patients treated with 
DEC (21). In contrast our data demonstrating no impact of TP53 on response rate to 
AZA but decreased OS in mutated patients implies that these two DNMT inhibitors 
may have distinct mechanisms of action (16, 20, 33).  
The development of strategies to overcome the inevitability of disease relapse in 
AML patients treated with AZA is essential if outcomes are to improve. It is 
postulated that disease recurrence in AML patients treated with either 
myelosuppressive chemotherapy or DNMT inhibitors occurs as a result of expansion 
of chemo-resistant LSC. However, correlative data in large cohorts of patients 
treated with either modality of therapy has been lacking. Thus, the demonstration in 
this study of LSC persistence in AZA treated patients who achieve a CR is consistent 
with the hypothesis that this recently identified cellular population may serve as a 
reservoir of resistant disease in AZA treated patients. These data contrast with 
observations in patients treated with conventional chemotherapy where durable 
clearance of LSC appears to correlate with long-term remission and highlight the 
potential importance of quantitation of this cellular population as a biomarker of 
response in future studies of novel AZA based combinations (4, 31, 32).  
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Tables 
Table 1. Demographics of study population 
 
       
  
Whole population 
(n=259) 
  
Azacitidine alone 
(n=129) 
  
Azacitidine + Vorinostat 
(n=130)  
  
  No. % No. % No. % 
Age, years             
< 70 years old 96 37 48 37 48 37 
≥70 years old 163 63 81 63 82 63 
Gender             
Male 156 60 75 58 81 62 
Female 103 40 54 42 49 38 
AML disease stage             
Newly Diagnosed 111 43 57 44 54 42 
Relapsed 73 28 34 26 39 30 
Refractory 33 13 17 13 16 12 
MDS disease stage             
Newly Diagnosed 36 14 16 12 20 15 
Relapsed 5 2 4 3 1 1 
Refractory 1 0 1 1 0 0 
ECOG performance status             
0 84 32 52 40 32 25 
1 133 51 63 49 70 54 
2 26 10 9 7 17 13 
Missing 16 6 5 4 11 8 
Cytogenetic group             
Favorable risk 13 5 2 2 11 8 
Intermediate risk 109 42 58 45 51 39 
Poor risk 54 21 26 20 28 22 
Risk not known/not done 73 28 38 29 35 27 
Missing 10 4 5 4 5 4 
Bone Marrow Morphology - % Blasts             
Mean 46.2 48 44.4 
SD 28.4 27.7 29.1 
Hemoglobin, g/L 
      
Mean 131.1 120.9 141.1 
SD 184.9 167.5 200.9 
Platelets, 10
9
/L 
      
Mean 85.4 78.1 92.7 
SD 131.2 79.2 167.7 
WCC, 10
9
/L 
      
Mean 14.1 15.6 12.6 
SD 24.6 29 19.4 
Neutrophils, 10
9
/L 
      
Mean 3.1 3 3.2 
SD 9.2 8.4 9.9 
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Table 2. Univariate and multivariate analysis of predictors of CR and OS in the 
study population 
 
Overall Response 
  Covariate 
Univariate analysis Multivariable analysis* 
OR (95% CI) P † OR (95% CI) P 
C
lin
ic
a
l 
v
a
ri
a
b
le
s
 
Disease Status   (<0.001)     
    Refractory (v Relapsed) 0.2 (0.1, 0.9) 0.03 Not estimable   
    Newly diagnosed (v Relapsed) 2.1 (1.0, 4.6) 0.051 3.6 (1.1, 11.7) 0.037 
Baseline WBC         
     ≥10 (v <10) 0.7 (0.3, 1.5) 0.39 0.5 (0.2, 1.8) 0.292 
Cytogenetic Risk   -0.416     
     Intermediate (v Poor) 0.6 (0.3, 1.3) 0.204 0.6 (0.2, 2.0) 0.424 
     Favorable (v Poor) 1.0 (0.2, 4.9) 0.951 0.8 (0.1, 5.6) 0.843 
Age         
     ≥70 (v <70) 1.3 (0.7, 2.5) 0.447 1.3 (0.4, 3.8) 0.674 
Diagnosis         
     AML (v MDS) 0.8 (0.4, 1.8) 0.649 1.0 (0.3, 3.7) 0.957 
ECOG P.S.   -0.98     
     1 (v 0) 1.0 (0.5, 1.9) 0.92 1.6 (0.6, 4.4) 0.395 
     2 (v 0) 1.1 (0.4, 3.2) 0.902 1.0 (0.2, 5.8) 0.981 
M
u
ta
ti
o
n
s
 
STAG2 mutation         
     Present (v Absent) 0.2 (0.1, 0.6) 0.002 0.3 (0.1, 1.4) 0.117 
IDH2 mutation         
     Present (v Absent) 0.4 (0.2, 0.9) 0.029 0.4 (0.1, 1.3) 0.139 
NPM1 mutation         
     Present (v Absent) 2.5 (1.0, 6.2) 0.038 8.6 (1.6, 45.8) 0.012 
Overall Survival 
  Covariate 
Median OS  Univariate analysis Multivariable analysis** 
(95% CI) , months HR (95% CI) P ‡ HR (95% CI) P  
C
lin
ic
a
l 
v
a
ri
a
b
le
s
 
Diagnosis           
     MDS 19.4 (11.3, 22.7) 1   1   
     AML 9.1 (8.0, 11.1) 2.0 (1.3, 3.0) 0.0008 2.3 (1.3, 4.3) 0.007 
Baseline WBC           
     <10 11.5 (9.8, 13.6) 1   1   
     ≥10 8.8 (6.7, 10.5) 1.5 (1.1, 2.0) 0.0116 2.2 (1.4, 3.5) 0.001 
Disease Status     -0.0132     
     Relapsed 7.6 (6.4, 10.5) 1   1   
     Refractory 9.8 (8.3, 13.2) 0.8 (0.5, 1.2) 0.218 1.0 (0.5, 1.8) 0.976 
     Newly diagnosed 11.7 (10.1, 14.9) 0.6 (0.5, 0.9) 0.005 0.5 (0.3, 0.8) 0.003 
ECOG P.S.     -0.0235     
0 12.7 (9.6, 19.4) 1   1   
1 10.1 (8.0, 11.5) 1.6 (1.1, 2.1) 0.009 1.6 (1.0, 2.6) 0.035 
2 9.5 (7.8, 15.4) 1.5 (0.9, 2.4) 0.0968 1.6 (0.9, 2.9) 0.131 
Age           
     <70 9.3 (7.6, 11.6) 1   1   
     ≥70 11.1 (9.0, 13.5) 0.8 (0.6, 1.1) 0.1706 1.6 (0.9, 1.8) 0.448 
Cytogenetic Risk     -0.8589     
     Poor 9.5 (7.1, 11.1) 1   1   
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     Intermediate 11.4 (8.1, 15.3) 0.9 (0.6, 1.3) 0.6367 1.2 (0.7, 1.9) 0.549 
     Favorable 12.0 (1.7, N/E) 0.8 (0.4, 1.8) 0.6392 1.1 (0.5, 2.8) 0.802 
M
u
ta
ti
o
n
s
 
CDKN2A mutation           
     Absent 11.0 (9.3, 12.6) 1   1   
     Present 4.5 (0.2, 7.8) 3.9 (1.9, 8.0) 0.0001 
10.0 (3.3, 
30.3) 
<0.001 
TP53 mutation           
     Absent 11.3 (9.4, 13.0) 1   1   
     Present 7.6 (2.4, 9.6) 1.8 (1.2, 2.6) 0.003 4.7 (2.5, 9.0) <0.001 
IDH1 mutation           
     Absent 11.1 (9.4, 12.7) 1   1   
     Present 5.6 (2.8, 9.8) 1.9 (1.2, 2.9) 0.004 3.6 (1.7, 7.6) 0.001 
NPM1 mutation           
     Absent 11.1 (9.1, 12.6) 1   1   
     Present 8.1 (5.6, 10.7) 1.5 (1.0, 2.2) 0.037 0.6 (0.4, 1.1) 0.122 
FLT3ITD mutation           
     Absent 11.1 (9.0, 12.7) 1   1   
     Present 8.8 (6.1, 11.6) 1.5 (1.0, 2.1) 0.04 1.0 (0.6, 1.8) 1 
           OR, Overall Response; WBC, White Blood Cell, ECOG P.S, Eastern Cooperative Oncology Group Performance 
Status, N/E, Not estimable 
* Logistic regression model adjusted for all variables in 
the table 
      † Given by the Chi-square or Fisher’s exact test, corresponding to pairwise comparisons or the overall 
comparison as indicated between parentheses 
** Cox Proportional Hazards model adjusted for all 
variables in the table 
      ‡ Given by the Log-rank test, corresponding to pairwise comparisons, or the overall comparison as indicated 
between parentheses 
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Figure Legends 
Figure 1 
Consort Diagram 
Schematic representation of patient disposition in the trial 
 
Figure 2 
Overall Survival of Trial Patients  
(a) Survival in all study patients 
 
(b) Survival in patients with AML 
 
 
(c) Survival in patients with MDS 
 
Figure 3 
Mutation profile of study population and correlation with clinical response.  
(a) Frequency of mutations (as % of patients) in patients at trial entry. Patients are 
further divided according to best response achieved.   
 
(b) Frequency of number of mutations detected per patient pre-treatment. 
 
(c) Comparison of mutations detected in RAvVA cohort compared with recently 
published AML cohorts (Papa: Papaemmanuil et al(19), TCGA(20), Welch et al(21)). 
 
(d) Correlation of combinations of detected mutations with CR and OS: only genes 
where there were at least 5 patients with 2 mutations are included in this analysis. 
Unadjusted p values from a Fisher exact test are shown. The top right half of the 
table (values in shades of green) show mutation combinations significantly 
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associated with decreased OS. The bottom left half of the table (with values in 
shades of yellow) shows absence of significant mutation combinations predictive of 
CR. Key: CR (includes CR, CRi), PR, NR (no response including stable disease and 
progressive disease), ID (induction death), NA (response data not available). 
 
 
Figure 4 
Flow cytometric measurement of LSC populations. 
(a) Quantitation of expanded CD34+ progenitor or CD34- precursor LSC populations 
in AML patients pre-treatment. 
 
(b) Quantitation of LMPP-like LSC pre-treatment and at CR expressed as fold 
change of upper limit of LMPP frequency in normal bone marrow (upper limit of 
normal, ULN, dotted line, assessed in 12 normal donors). 
 
(c) Longitudinal quantitation of LMPP-like LSC in patients pre-treatment, at CR 
(multiple time points in 2 patients: CR’ and CR’’) and at relapse. 
 











